HOME >> MEDICINE >> NEWS
Aventis Pasteur statement on HVTN 501 decision

Aventis Pasteur remains committed to the continued development of its ALVAC vector as a preventive AIDS vaccine. The knowledge gleaned from HIV Vaccine Trials Network (HVTN) 203 will be useful in moving future studies forward both in the U.S. and internationally.

There is no known correlate of protection for HIV vaccines. HVTN 501 was designed to determine possible correlates in addition to looking at efficacy of a prime-boost combination, using an ALVAC-HIV (vCP1452) prime and a gp120 boost. Because a correlate of protection analysis would not be able to be obtained from HVTN 501, that trial will not proceed. The decision, made by the NIAID and HVTN, was based on a review of data from HVTN 203 and is supported by the company.

However, the opportunity to see if the prime-boost, using ALVAC-HIV and gp120, is efficacious remains imminent. A phase III trial to be undertaken in Thailand with the Thai government and Walter Reed Army Institute of Research is planned to begin later this year. The Thai trial and HVTN 501 had different objectives. The Thai study is a straightforward community-based trial with efficacy as its outcome. The company will cooperate fully with the trial.

The NIAID and HVTN remain fully committed to several other trials using ALVAC-HIV (vCP1452) and the company intends to support them. HVTN (HIVNET) 026 looks at the safety and immunogenicity of ALVAC-HIV (vCP1452) and gp120 MN in populations outside of the U.S. HVTN 039 is studying whether a higher dose level of ALVAC-HIV (vCP1452) results in an enhanced HIV-specific immune response in vaccinees. HVTN 042 will seek to determine if there is a benefit to using a different boost, in this case lipopeptides and is in collaboration with the Agence Nationale de Recherche Sur de Sida (ANRS).

Importantly, all of these trials will help guide the companys R and D efforts in this area as well as build a continuing record of safety for these approaches. AL
'"/>

Contact: Robert Sebbag/Beth Waters
33-60-817-2183
Cooney Waters Group, Inc.
25-Feb-2002


Page: 1 2

Related medicine news :

1. Aventis Pasteur ready to meet nations needs for tetanus and diphtheria vaccine
2. Aventis Pasteur donates approximately 75 to 90 million doses of smallpox vaccine to the U.S.
3. Millennium, Aventis Pharma form novel alliance
4. Aventis Pharmaceuticals Allegra (Fexofenadine Hcl) 30-Mg tablets now available to treat seasonal allergies, chronic hives in children 6 to 11 years
5. NHLBI statement on oral contraceptive study
6. NIH panel issues State-of-the-Science statement on end-of-life care
7. Doctors statement in Mayo Clinic Proceedings reveals dark side of low-carb diets
8. American Heart Association consensus statement
9. NIA statement on IOM testosterone report
10. American Psychiatric Association issues statement on compulsive shopping
11. New statement proposes ways to stop deadly drug errors among heart, stroke patients

Post Your Comments:
*Name:
*Comment:
*Email:
TAG: Aventis Pasteur statement HVTN decision

(Date:8/1/2014)... (PRWEB) August 01, 2014 Stryker ... wake of the 2012 Rejuvenate and ABG II ... in New Jersey’s Bergen County Superior Court, Bernstein ... the proceeding, the Court has issued a ... any and all hard copy and electronic materials ...
(Date:8/1/2014)... Ohio In a first-of-its-kind study, researchers at University ... that lap infants may be at greater risk for ... pediatric medical emergencies on flights worldwide between January 2010 ... occurred in children under the age of 2. ... to characterize the rare event of an in-flight pediatric ...
(Date:8/1/2014)... 2014 The evolving healthcare landscape ... pharmacies. At ThoughtSpot 2014, AmerisourceBergen and Good Neighbor ... and resources to enhance patient care and profitability. ... critical issues to give independent pharmacists the tools ... , ThoughtSpot show attendance experienced a nearly 70% ...
(Date:8/1/2014)... down fears, emotions and the benefits of a cancer ... survivors, according to a study conducted by a researcher ... key to developing an expressive writing intervention is the ... recording facts and events. Writing a journal can be ... to determine whether it,s effective or not," said Qian ...
(Date:8/1/2014)... August 01, 2014 Market Publishers ... reports have been added to its catalogue. ... Pharmaceutical Ingredients (APIs), Contract Research and Manufacturing Services ... pharma industry drivers include, among others, increasing ageing ... hygiene. In 2015, the pharma market in India ...
Breaking Medicine News(10 mins):Health News:Stryker Hip Lawsuit News: New Order Issued in New Jersey Stryker Hip Recall Litigation, Bernstein Liebhard LLP Reports 2Health News:Stryker Hip Lawsuit News: New Order Issued in New Jersey Stryker Hip Recall Litigation, Bernstein Liebhard LLP Reports 3Health News:New research characterizes in-flight pediatric deaths 2Health News:ThoughtSpot 2014 Inspires as General Session Concludes 2Health News:ThoughtSpot 2014 Inspires as General Session Concludes 3Health News:ThoughtSpot 2014 Inspires as General Session Concludes 4Health News:ThoughtSpot 2014 Inspires as General Session Concludes 5Health News:Expressive writing may help breast cancer survivors 2Health News:Expressive writing may help breast cancer survivors 3Health News:In-demand Markets Research Reports by Kelly Scientific Publications Now Available at MarketPublishers.com 2Health News:In-demand Markets Research Reports by Kelly Scientific Publications Now Available at MarketPublishers.com 3
(Date:8/1/2014)... Aug. 1, 2014 In the latest call ... sexual dysfunction, more than 60 doctors and leading medical ... letter questioning the Food and Drug Administration,s (FDA) decision ... form of male sexual dysfunction compared with ZERO for ... to act for women by approving the first-ever drug ...
(Date:8/1/2014)... 1, 2014 Aspire Technology Partners (Aspire) announced today ... from Cisco. This designation recognizes Aspire for delivering outstanding customer ... America . "Achieving exceptional results for our ... Harris , President and CEO of Aspire. "We are pleased ... Gold Star award and are proud to be part of ...
(Date:8/1/2014)... , Ill. and PALO ALTO, Calif. ... Cystic Fibrosis Research, Inc. (CFRI) today announced a partnership ... cystic fibrosis (CF) community through the CFChef Shares program. ... 15, 2014, as part of AbbVie,s CFChef program – ... to encourage patients to maintain a healthy diet by ...
Breaking Medicine Technology:60+ Doctors and Leading Medical Experts Sign an Open Letter Urging the FDA to Approve First-Ever Drug to Treat Women's Most Common Form of Sexual Dysfunction, notes Even the Score 260+ Doctors and Leading Medical Experts Sign an Open Letter Urging the FDA to Approve First-Ever Drug to Treat Women's Most Common Form of Sexual Dysfunction, notes Even the Score 3Aspire Technology Partners Recognized By Cisco For Excellence In Customer Satisfaction 2AbbVie and Cystic Fibrosis Research, Inc. (CFRI) Team Up to Raise Awareness of the Nutritional Needs of CF Patients through the CFChef Shares Program 2AbbVie and Cystic Fibrosis Research, Inc. (CFRI) Team Up to Raise Awareness of the Nutritional Needs of CF Patients through the CFChef Shares Program 3
Cached News: